surmount-1 trial tirzepatide weight loss nondiabetic Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 Dose-Dependent Efficacy and Safety of
Description
Vitamin B12 monitoring is not routinely indicated for patients on GLP-1/GIP therapy alone but may be considered for those also taking metformin or with risk factors for deficiency
Shipping, customer service, and the ordering experience Peptide Sciences handles logistics well
This slow build exists for good reason
The SURMOUNT-1 trial showed 22.5% average weight loss with tirzepatide at 15 mg, compared to 14.9% with semaglutide at 2.4 mg in the STEP-1 trial
September 2022
